Biotech Values

[genisi]

Is this a drug that, if successful, CYPB could bring to market on its own or would they need to further enter into a deal with a big pharma?

Data from phase IIb trial showed improved cognitive function #msg-41779373 and I assume this is how CYPB would try to distinct this drug from other antipsychotic drugs in the schizophrenia market but the regulatory path is not clear from here - will the drug proceed straight to phase III or will another phase IIb be required and how big the trial/s will be. So, there's a reasonable chance CYPB will need a big pharma partner in order to bring this drug to the market.